EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS

Official Journal of the International Association for Pharmaceutical Technology

AUTHOR INFORMATION PACK

TABLE OF CONTENTS

ISSN: 0939-6411

- **Description** **p.1**
- **Audience** **p.1**
- **Impact Factor** **p.2**
- **Abstracting and Indexing** **p.2**
- **Editorial Board** **p.2**
- **Guide for Authors** **p.4**

DESCRIPTION

The *European Journal of Pharmaceutics and Biopharmaceutics* provides a medium for publication of novel and innovative research from the areas of Pharmaceutical Technology, Pharmaceutical Biotechnology and Biopharmaceutics.

Topics covered include:

- Drug and pro-drug design, drug stability and drug development
- Development, formulation and manufacturing of pharmaceuticals and biopharmaceuticals
- Physical pharmacy, drug delivery systems, controlled release systems and drug targeting
- Biopharmaceutics
- Pharmaceutical analysis and pharmaceutical packaging
- Quality control, GMP and regulatory aspects
- Medical devices

"The Rules of 3"
The Editors and Editorial board have developed the "Rules of 3". Authors must consider the following three criteria before they submit a manuscript and set the whole process of editing and reviewing at work:

1. The paper must report on recent advances in pharmaceutical technology, biopharmaceutics and pharmaceutical biotechnology of major importance
2. A paper must be based on a thorough and extensive study, using established or well-described methods and including proper controls. Research must be hypothesis-driven and conclusions must be supported by the data presented.
3. The study described in the manuscript must represent a novel approach

The rules are also used as guidelines for the peer review of manuscripts. CLICK HERE to view the "Rules of 3".

AUDIENCE

Pharmaceutical Scientists, Chemical Engineers, Pharmaceutical and Biopharmaceutical Scientists, Medicinal Chemists, Pharmacologists, Analytical Chemists, Clinical Pharmacologists, Pharmaceutical Engineers

IMPACT FACTOR

2012: 3.826 © Thomson Reuters Journal Citation Reports 2013

ABSTRACTING AND INDEXING

MEDLINE®
International Pharmaceutical Abstracts
PASCAL M
CAB Abstracts
BIOSIS/Biological Abstracts
Chemical Abstracts Service
EMBASE/Excerpta Medica
Scopus
Science Citation Index Expanded

EDITORIAL BOARD

Editor-in-Chief:

A. Goepferich, Department of Chemistry and Pharmaceutical Sciences, University of Regensburg, Universitaetsstrasse 31, 93040, Regensburg, Germany

Assistant Editor:

F. Brandl, University of Regensburg, Regensburg, Germany
M. Breunig, University of Regensburg, Regensburg, Germany

Editors:

J. Dressman, Goethe-Universität Frankfurt, Frankfurt, Germany
W. Friess, Ludwig-Maximilians-Universität München (LMU), München, Germany
G. Lee, Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany
C.-M. Lehr, Helmholtz-Institute for Pharmaceutical Research and Saarland University, Saarbrücken, Germany
L. Meinel, Julius-Maximilians-Universität Würzburg, Würzburg, Germany
K. Mäder, Martin-Luther-Universität Halle-Wittenberg, Halle/Saale, Germany
M. Möller, Université de Genève, Geneva, Switzerland
D. Putnam, Cornell University, Ithaca, New York, USA
T. Rades, University of Copenhagen, Copenhagen, Denmark
M.J. Rathbone, International Medical University, Kuala Lumpur, Malaysia

Editorial Board:

E. Allémann, Université de Genève, Geneva, Switzerland
M.J. Alonso, Universidade de Santiago de Compostela, Santiago de Compostela, Spain
J.M. Anderson, Case Western Reserve University School of Medicine, Cleveland, Ohio, USA
J.-P. Benoit, INSERM, Angers, France
A. Bernkop-Schnürch, Leopold-Franzens-Universität Innsbruck, Innsbruck, Austria
M.J. Blanco-Prieto, Universidad de Navarra, Pamplona, Spain
R. Bodmeier, Freie Universität Berlin, Berlin, Germany
J. Breitenbach, Abbott Gmbh & Co. KG, Ludwigshafen, Germany
J. Breitkreutz, Heinrich-Heine-Universität Düsseldorf, Düsseldorf, Germany
H. Bunjes, Technische Universität Braunschweig, Braunschweig, Germany
M. Capelle, Therapeomic AG, Basel, Switzerland
U. Conte, Università degli Studi di Pavia, Pavia, Italy
P. Couvreur, Université Paris-Sud (Paris XI), Châtenay-Malabry, France
R. Daniels, Eberhard-Karls-Universität Tübingen, Tübingen, Germany
F. Delie-Salmon, Université de Genève, Geneva 4, Switzerland
B. Demeule, Genentech, Inc., San Francisco, California, USA
T. Desai, University of California at San Francisco (UCSF), San Francisco, California, USA
J.-M. Devoisselle, UFR des Sciences Pharmaceutics et Biologiques, Montpellier, France
E. Doelker, Université de Genève, Geneva 4, Switzerland
P. Esposito, SiTec PharmaBio, Barcelona, Spain
C. Fischbach-Teschl, Cornell University, Ithaca, New York, USA
G. Fricker, Institut für Pharmazie und Molekulare Biotechnologie, Heidelberg, Germany
B. Gander
P. Gershkovich, University of Nottingham, Nottingham, UK

W.R. Gombotz, Omeros Corp., Seattle, Washington, USA
M.A. Gonzalez, P'Kinetics International Inc., Pembroke Pines, Florida, USA
R.H. Guy, University of Bath, Bath, UK
J. Hadgraft, University of London, London, UK
J. Hanes, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA
M. Horstmann, Acino Pharma AG, Aesch, Switzerland
J.A. Hubbell, École Polytechnique Fédérale de Lausanne (EPFL), Lausanne, Switzerland
H.E. Junginger
Y.N. Kalia, Université de Genève, Geneva 4, Switzerland
T. Kissel, Philipps-Universität Marburg, Marburg, Germany
S. Klein, Ernst-Moritz-Arnd Universität Greifswald, Greifswald, Germany
P. Kleinebudde, Heinrich-Heine-Universität Düsseldorf, Düsseldorf, Germany
J. Kopecek
J. Kreuter, Goethe-Universität Frankfurt, Frankfurt, Germany
S. Küchler, Freie Universität Berlin, Berlin, Germany
N. Lange, Université de Genève, Geneva, Switzerland
H. Lindner, Bayer Schering Pharma AG, Berlin, Germany
E. Mathiowitz, Brown University, Providence, Rhode Island, USA
A.G. Mikos, Rice University, Houston, Texas, USA
D. Mooney, Harvard School of Engineering and Applied Sciences, Cambridge, Maryland, USA
R.H. Müller, Freie Universität Berlin, Berlin, Germany
C. Müller-Goymann, Technische Universität Braunschweig, Braunschweig, Germany
T. Nagai, Nagai Foundation Tokyo, Tokyo, Japan
R.H.H. Neubert, Martin-Luther-Universität Halle-Wittenberg, Halle/Saale, Germany
G.M. Pauletti, University of Cincinnati Medical Center, Cincinnati, Ohio, USA
N.A. Peppas, University of Texas, Austin, Texas, USA
V. Préat, Université Catholique de Louvain, Brussels, Belgium
K. Roy, University of Texas at Austin, Austin, Texas, USA
S. Rudaz, Université de Genève, Geneva, Switzerland
C. Rudolph, Ludwig-Maximilians-Universität München (LMU), München, Germany
L. Scapozza, Université de Genève, Geneva, Switzerland
R. Schubert, Albert-Ludwigs-Universität Freiburg, Freiburg, Germany
J. Siepmann, Université Lille Nord de France, Lille, France
Y. Tabata, Kyoto University, Sakyo-ku, Kyoto, Japan
V.P. Torchilin, Northeastern University, Boston, Massachusetts, USA
C. Valenta, University of Vienna, Wien, Austria
K. Wasan, University of British Columbia, Vancouver, British Columbia, Canada
W. Weitschies, Ernst-Moritz-Arnd Universität Greifswald, Greifswald, Germany
C.G. Wilson, University of Strathclyde, Glasgow, UK
G. Winter, Ludwig-Maximilians-Universität München (LMU), München, Germany
A. Zimmer, Technische Universität Graz, Graz, Austria
A.F. Öner, Hacettepe University, Hacettepe, Ankara, Turkey

Honorary Editor:

R. Gurny, Université de Genève, Geneva, Switzerland

GUIDE FOR AUTHORS

Your Paper Your Way
ypyw-gfa-banner.gifyour paper your way

INTRODUCTION

The *European Journal of Pharmaceutics and Biopharmaceutics* provides a medium for publication of novel and innovative research from areas of pharmaceutical technology, drug delivery systems, controlled release systems, drug targeting, physical pharmacy, biopharmaceutics, drug development, drug and prodrug design, pharmaceutical analysis, drug stability, quality control, GMP, regulatory aspects, pharmaceutical packaging, and phytochemistry.

The pharmaceutical biotechnology section provides a forum for the publication of papers on scientific, developmental, regulatory and manufacturing issues concerning the development of biopharmaceuticals, uniquely combining expert contributions and opinions of authors from the fields of pharmaceutics and biotechnology. This scope encompasses modern biopharmaceuticals (e.g., proteins and nucleic acids), biosimilars/biogenerics as well as 'traditional' products such as antibiotics.

"THE RULES OF 3"
The Editors and Editorial board have developed the "Rules of 3". Authors must consider the following three criteria before they submit a manuscript and set the whole process of editing and reviewing at work. The rules are also used as guidelines for the peer review of manuscripts. CLICK HERE to view the "Rules of 3".

Authors are encouraged to submit video material or animation sequences to support and enhance your scientific research. For more information please see the paragraph on video data below.

Types of paper
The following types of papers are considered by the Editors: Research Papers, Review Articles, Short Reviews, and Notes.

BEFORE YOU BEGIN

Ethics in publishing
For information on Ethics in publishing and Ethical guidelines for journal publication see http://www.elsevier.com/publishingethics and http://www.elsevier.com/journal-authors/ethics.

Human and animal rights
If the work involves the use of animal or human subjects, the author should ensure that the work described has been carried out in accordance with The Code of Ethics of the World Medical Association (Declaration of Helsinki) for experiments involving humans http://www.wma.net/en/30publications/10policies/b3/index.html; EU Directive 2010/63/EU for animal experiments http://ec.europa.eu/environment/chemicals/lab_animals/legislation_en.htm; Uniform Requirements for manuscripts submitted to Biomedical journals http://www.icmje.org. Authors should include a statement in the manuscript that informed consent was obtained for experimentation with human subjects. The privacy rights of human subjects must always be observed.

Conflict of interest
All authors are requested to disclose any actual or potential conflict of interest including any financial, personal or other relationships with other people or organizations within three years of beginning the submitted work that could inappropriately influence, or be perceived to influence, their work. See also http://www.elsevier.com/conflictsofinterest. Further information and an example of a Conflict of Interest form can be found at: http://help.elsevier.com/app/answers/detail/a_id/286/p/7923.

Submission declaration
Submission of an article implies that the work described has not been published previously (except in the form of an abstract or as part of a published lecture or academic thesis or as an electronic preprint, see http://www.elsevier.com/postingpolicy), that it is not under consideration for publication elsewhere, that its publication is approved by all authors and tacitly or explicitly by the responsible authorities where the work was carried out, and that, if accepted, it will not be published elsewhere including electronically in the same form, in English or in any other language, without the written consent of the copyright-holder.

Changes to authorship

This policy concerns the addition, deletion, or rearrangement of author names in the authorship of accepted manuscripts:

Before the accepted manuscript is published in an online issue: Requests to add or remove an author, or to rearrange the author names, must be sent to the Journal Manager from the corresponding author of the accepted manuscript and must include: (a) the reason the name should be added or removed, or the author names rearranged and (b) written confirmation (e-mail, fax, letter) from all authors that they agree with the addition, removal or rearrangement. In the case of addition or removal of authors, this includes confirmation from the author being added or removed. Requests that are not sent by the corresponding author will be forwarded by the Journal Manager to the corresponding author, who must follow the procedure as described above. Note that: (1) Journal Managers will inform the Journal Editors of any such requests and (2) publication of the accepted manuscript in an online issue is suspended until authorship has been agreed.

After the accepted manuscript is published in an online issue: Any requests to add, delete, or rearrange author names in an article published in an online issue will follow the same policies as noted above and result in a corrigendum.

Article transfer service

This journal is part of our Article Transfer Service. This means that if the Editor feels your article is more suitable in one of our other participating journals, then you may be asked to consider transferring the article to one of those. If you agree, your article will be transferred automatically on your behalf with no need to reformat. More information about this can be found here: http://www.elsevier.com/authors/article-transfer-service.

Copyright

This journal offers authors a choice in publishing their research: Open Access and Subscription.

For Subscription articles

Upon acceptance of an article, authors will be asked to complete a 'Journal Publishing Agreement' (for more information on this and copyright, see http://www.elsevier.com/copyright). An e-mail will be sent to the corresponding author confirming receipt of the manuscript together with a 'Journal Publishing Agreement' form or a link to the online version of this agreement.

Subscribers may reproduce tables of contents or prepare lists of articles including abstracts for internal circulation within their institutions. Permission of the Publisher is required for resale or distribution outside the institution and for all other derivative works, including compilations and translations (please consult http://www.elsevier.com/permissions). If excerpts from other copyrighted works are included, the author(s) must obtain written permission from the copyright owners and credit the source(s) in the article. Elsevier has preprinted forms for use by authors in these cases: please consult http://www.elsevier.com/permissions.

For Open Access articles

Upon acceptance of an article, authors will be asked to complete an 'Exclusive License Agreement' (for more information see http://www.elsevier.com/OAauthoragreement). Permitted reuse of open access articles is determined by the author's choice of user license (see http://www.elsevier.com/openaccesslicenses).

Retained author rights

As an author you (or your employer or institution) retain certain rights. For more information on author rights for:

Subscription articles please see http://www.elsevier.com/journal-authors/author-rights-and-responsibilities.

Open access articles please see http://www.elsevier.com/OAauthoragreement.

Role of the funding source

You are requested to identify who provided financial support for the conduct of the research and/or preparation of the article and to briefly describe the role of the sponsor(s), if any, in study design; in the collection, analysis and interpretation of data; in the writing of the report; and in the decision to submit the article for publication. If the funding source(s) had no such involvement then this should be stated.

Funding body agreements and policies

Elsevier has established agreements and developed policies to allow authors whose articles appear in journals published by Elsevier, to comply with potential manuscript archiving requirements as specified as conditions of their grant awards. To learn more about existing agreements and policies please visit http://www.elsevier.com/fundingbodies.

Open access

This journal offers authors a choice in publishing their research:

Open Access
• Articles are freely available to both subscribers and the wider public with permitted reuse
• An Open Access publication fee is payable by authors or their research funder
Subscription
• Articles are made available to subscribers as well as developing countries and patient groups through our access programs (http://www.elsevier.com/access)
• No Open Access publication fee

All articles published Open Access will be immediately and permanently free for everyone to read and download. Permitted reuse is defined by your choice of one of the following Creative Commons user licenses:
Creative Commons Attribution (CC BY): lets others distribute and copy the article, to create extracts, abstracts, and other revised versions, adaptations or derivative works of or from an article (such as a translation), to include in a collective work (such as an anthology), to text or data mine the article, even for commercial purposes, as long as they credit the author(s), do not represent the author as endorsing their adaptation of the article, and do not modify the article in such a way as to damage the author's honor or reputation.
Creative Commons Attribution-NonCommercial-ShareAlike (CC BY-NC-SA): for non-commercial purposes, lets others distribute and copy the article, to create extracts, abstracts and other revised versions, adaptations or derivative works of or from an article (such as a translation), to include in a collective work (such as an anthology), to text and data mine the article, as long as they credit the author(s), do not represent the author as endorsing their adaptation of the article, do not modify the article in such a way as to damage the author's honor or reputation, and license their new adaptations or creations under identical terms (CC BY-NC-SA).
Creative Commons Attribution-NonCommercial-NoDerivs (CC BY-NC-ND): for non-commercial purposes, lets others distribute and copy the article, and to include in a collective work (such as an anthology), as long as they credit the author(s) and provided they do not alter or modify the article.

To provide Open Access, this journal has a publication fee which needs to be met by the authors or their research funders for each article published Open Access.
Your publication choice will have no effect on the peer review process or acceptance of submitted articles.

The open access publication fee for this journal is **$3000**, excluding taxes. Learn more about Elsevier's pricing policy: http://www.elsevier.com/openaccesspricing.

Language (usage and editing services)

Please write your text in good English (American or British usage is accepted, but not a mixture of these). Authors who feel their English language manuscript may require editing to eliminate possible grammatical or spelling errors and to conform to correct scientific English may wish to use the English Language Editing service available from Elsevier's WebShop (http://webshop.elsevier.com/languageediting/) or visit our customer support site (http://support.elsevier.com) for more information.

Submission

Submission to this journal proceeds totally online and you will be guided stepwise through the creation and uploading of your files. The system automatically converts source files to a single PDF file of the article, which is used in the peer-review process. Please note that even though manuscript source files are converted to PDF files at submission for the review process, these source files are needed for further processing after acceptance. All correspondence, including notification of the Editor's decision and requests for revision, takes place by e-mail removing the need for a paper trail.

Referees
You are requested to name at least 5 international experts as possible reviewers for your manuscript, providing their names, affiliations and email addresses.

Please note that the reviewers you suggest should: not be from the same country as you not have been collaborators of yours in the past 2 years not be members of the Editorial Board of the journal

Additional information

US National Institutes of Health (NIH) voluntary posting ("Public Access") policy.

Elsevier facilitates author posting in connection with the voluntary posting request of the NIH (referred to as the NIH "Public Access Policy"; see http://publicaccess.nih.gov/) by posting the peer-reviewed author's manuscript directly to PubMed Central on request from the author, after formal publication. Upon notification from Elsevier of acceptance, we will ask you to confirm via e-mail (by e-mailing us at NIHauthorrequest@elsevier.com) that your work has received NIH funding (with the NIH award number, as well as the name and e-mail address of the Prime Investigator) and that you intend to respond to the NIH request. Upon such confirmation, Elsevier will submit to PubMed Central on your behalf a version of your manuscript that will include peer-review comments, for posting 12 months after the formal publication date. This will ensure that you will have responded fully to the NIH request policy. There will be no need for you to post your manuscript directly with PubMed Central, and any such posting is prohibited. Individual modifications to this general policy may apply to some Elsevier journals and its society publishing partners.

PREPARATION

NEW SUBMISSIONS

Submission to this journal proceeds totally online and you will be guided stepwise through the creation and uploading of your files. The system automatically converts your files to a single PDF file, which is used in the peer-review process.
As part of the Your Paper Your Way service, you may choose to submit your manuscript as a single file to be used in the refereeing process. This can be a PDF file or a Word document, in any format or layout that can be used by referees to evaluate your manuscript. It should contain high enough quality figures for refereeing. If you prefer to do so, you may still provide all or some of the source files at the initial submission. Please note that individual figure files larger than 10 MB must be uploaded separately.

References

There are no strict requirements on reference formatting at submission. References can be in any style or format as long as the style is consistent. Where applicable, author(s) name(s), journal title/book title, chapter title/article title, year of publication, volume number/book chapter and the pagination must be present. Use of DOI is highly encouraged. The reference style used by the journal will be applied to the accepted article by Elsevier at the proof stage. Note that missing data will be highlighted at proof stage for the author to correct.

Formatting requirements

There are no strict formatting requirements but all manuscripts must contain the essential elements needed to convey your manuscript, for example Abstract, Keywords, Introduction, Materials and Methods, Results, Conclusions, Artwork and Tables with Captions.
If your article includes any Videos and/or other Supplementary material, this should be included in your initial submission for peer review purposes.
Divide the article into clearly defined sections.

Figures and tables embedded in text
Please ensure the figures and the tables included in the single file are placed next to the relevant text in the manuscript, rather than at the bottom or the top of the file.

REVISED SUBMISSIONS

Use of word processing software
Regardless of the file format of the original submission, at revision you must provide us with an editable file of the entire article. Keep the layout of the text as simple as possible. Most formatting codes will be removed and replaced on processing the article. The electronic text should be prepared in a way very similar to that of conventional manuscripts (see also the Guide to Publishing with Elsevier: http://www.elsevier.com/guidepublication). See also the section on Electronic artwork.
To avoid unnecessary errors you are strongly advised to use the 'spell-check' and 'grammar-check' functions of your word processor.

LaTeX
You are recommended to use the Elsevier article class *elsarticle.cls* (http://www.ctan.org/tex-archive/macros/latex/contrib/elsarticle) to prepare your manuscript and BibTeX (http://www.bibtex.org) to generate your bibliography.
For detailed submission instructions, templates and other information on LaTeX, see http://www.elsevier.com/latex.

RESEARCH PAPERS

Should contain the following sections: Introduction, Theoretical Development (if applicable), Materials and Methods, Results, Discussion (or Results and Discussion) and References. For purely theoretical papers, appropriate sections may be selected.

It should define the purpose of the research and reveal its connections with the principal work of other authors in the field.

Materials and methods
It should include materials, standard techniques and procedures relevant to the study. Published procedures and techniques should be cited unless significant modifications are involved. Exact specification of relevant materials and equipment must be given. Chemical terms must conform with IUPAC rules. Trademarks of commercial products must be labelled using a superscripted '(r)'. Names of products and equipment mentioned in the Materials and Methods section must be accompanied by the name of the manufacturer or distributor, location and state or country. This information must be stated in parentheses in the text, and not as a footnote. Any potential hazards connected with materials and procedures must be mentioned. A precise and detailed description should be given of those steps which are of vital importance in carrying out any repetition of the work. The Declarations of Helsinki and Tokyo for humans, and the European Community guidelines as accepted principles for the use of experimental animals, must be adhered to. Therefore, *EJPB* will only consider manuscripts that describe experiments that have been carried out under approval of an institutional or local ethics committee. **Authors must state in the manuscript that the protocol complies with the particular recommendation and that approval of their protocols was obtained.**

Equations must be part of the text and consecutively numbered on the right hand side using numbers in parentheses. References to equations in the text are also to be made with parentheses, e.g. using Eq. (3), etc.

Organic formulas, both in figures and in the text, should be numbered in boldface arabic numerals.

SI units must be used throughout.

Theory/calculation
A Theory section should extend, not repeat, the background to the article already dealt with in the Introduction and lay the foundation for further work. In contrast, a Calculation section represents a practical development from a theoretical basis.

Results
Results may be presented in tables, figures or schemes which must be referred to in the accompanying text, using appropriate numbering, e.g. Fig. 1, Table 2.

Discussion
It should focus on the interpretation of the results. It might be appropriate to combine RESULTS AND DISCUSSION in one section. If necessary at all, use CONCLUSIONS only to illustrate the general implication of the results and do not summarize the previous text.

Conclusions
The main conclusions of the study may be presented in a short Conclusions section, which may stand alone or form a subsection of a Discussion or Results and Discussion section.

Appendices
If there is more than one appendix, they should be identified as A, B, etc. Formulae and equations in appendices should be given separate numbering: Eq. (A.1), Eq. (A.2), etc.; in a subsequent appendix, Eq. (B.1) and so on. Similarly for tables and figures: Table A.1; Fig. A.1, etc.

Essential title page information

• ***Title.*** Concise and informative. Titles are often used in information-retrieval systems. Avoid abbreviations and formulae where possible.
• ***Author names and affiliations.*** Where the family name may be ambiguous (e.g., a double name), please indicate this clearly. Present the authors' affiliation addresses (where the actual work was done) below the names. Indicate all affiliations with a lower-case superscript letter immediately after the author's name and in front of the appropriate address. Provide the full postal address of each affiliation, including the country name and, if available, the e-mail address of each author.
• ***Corresponding author.*** Clearly indicate who will handle correspondence at all stages of refereeing and publication, also post-publication. **Ensure that phone numbers (with country and area code) are provided in addition to the e-mail address and the complete postal address. Contact details must be kept up to date by the corresponding author.**
• ***Present/permanent address.*** If an author has moved since the work described in the article was done, or was visiting at the time, a 'Present address' (or 'Permanent address') may be indicated as a footnote to that author's name. The address at which the author actually did the work must be retained as the main, affiliation address. Superscript Arabic numerals are used for such footnotes.

It should contain a brief and clear description of the aim of the paper, its principal results and major conclusions (100--200 words). The abstract should include all keywords pertinent to the subject.

Graphical abstract

A Graphical abstract is mandatory for this journal. It should summarize the contents of the article in a concise, pictorial form designed to capture the attention of a wide readership online. Authors must provide images that clearly represent the work described in the article. Graphical abstracts should be submitted as a separate file in the online submission system. Image size: please provide an image with a minimum of 531 × 1328 pixels (h × w) or proportionally more. The image should be readable at a size of 5 × 13 cm using a regular screen resolution of 96 dpi. Preferred file types: TIFF, EPS, PDF or MS Office files. See http://www.elsevier.com/graphicalabstracts for examples.
Authors can make use of Elsevier's Illustration and Enhancement service to ensure the best presentation of their images also in accordance with all technical requirements: Illustration Service.

Keywords

Indicate 5 to 10 English keywords. They should be carefully selected in order to improve accessibility of scientific information in the manuscript. Keywords commonly used in international abstracting services will be preferred.

Chemical compounds

You can enrich your article by providing a list of chemical compounds studied in the article. The list of compounds will be used to extract relevant information from the NCBI PubChem Compound database and display it next to the online version of the article on ScienceDirect. You can include up to 10 names of chemical compounds in the article. For each compound, please provide the PubChem CID of the most relevant record as in the following example: Glutamic acid (PubChem CID:611). The PubChem CIDs can be found via http://www.ncbi.nlm.nih.gov/pccompound. Please position the list of compounds immediately below the 'Keywords' section. It is strongly recommended to follow the exact text formatting as in the example below:
Chemical compounds studied in this article
Ethylene glycol (PubChem CID: 174); Plitidepsin (PubChem CID: 44152164); Benzalkonium chloride (PubChem CID: 15865)
More information is available at: http://www.elsevier.com/PubChem.

Abbreviations

Define abbreviations that are not standard in this field in a footnote to be placed on the first page of the article. Such abbreviations that are unavoidable in the abstract must be defined at their first mention there, as well as in the footnote. Ensure consistency of abbreviations throughout the article.

Acknowledgements
Acknowledgements of financial support, gifts, technical help or other assistance may be given in an unnumbered paragraph under this heading preceding the references.

Database linking
Elsevier encourages authors to connect articles with external databases, giving their readers one-click access to relevant databases that help to build a better understanding of the described research. Please refer to relevant database identifiers using the following format in your article: Database: xxxx (e.g., TAIR: AT1G01020; CCDC: 734053; PDB: 1XFN). See http://www.elsevier.com/databaselinking for more information and a full list of supported databases.

Math formulae
Present simple formulae in the line of normal text where possible and use the solidus (/) instead of a horizontal line for small fractional terms, e.g., X/Y. In principle, variables are to be presented in italics. Powers of e are often more conveniently denoted by exp. Number consecutively any equations that have to be displayed separately from the text (if referred to explicitly in the text).

Footnotes
Footnotes should be used sparingly. Number them consecutively throughout the article. Many wordprocessors build footnotes into the text, and this feature may be used. Should this not be the case, indicate the position of footnotes in the text and present the footnotes themselves separately at the end of the article. Do not include footnotes in the Reference list.
Table footnotes
Indicate each footnote in a table with a superscript lowercase letter.

Artwork
Electronic artwork
General points
• Make sure you use uniform lettering and sizing of your original artwork.
• Preferred fonts: Arial (or Helvetica), Times New Roman (or Times), Symbol, Courier.
• Number the illustrations according to their sequence in the text.
• Use a logical naming convention for your artwork files.
• Indicate per figure if it is a single, 1.5 or 2-column fitting image.
• For Word submissions only, you may still provide figures and their captions, and tables within a single file at the revision stage.
• Please note that individual figure files larger than 10 MB must be provided in separate source files.
A detailed guide on electronic artwork is available on our website:
http://www.elsevier.com/artworkinstructions.
You are urged to visit this site; some excerpts from the detailed information are given here.
Formats
Regardless of the application used, when your electronic artwork is finalized, please 'save as' or convert the images to one of the following formats (note the resolution requirements for line drawings, halftones, and line/halftone combinations given below):
EPS (or PDF): Vector drawings. Embed the font or save the text as 'graphics'.
TIFF (or JPG): Color or grayscale photographs (halftones): always use a minimum of 300 dpi.
TIFF (or JPG): Bitmapped line drawings: use a minimum of 1000 dpi.
TIFF (or JPG): Combinations bitmapped line/half-tone (color or grayscale): a minimum of 500 dpi is required.
Please do not:
• Supply files that are optimized for screen use (e.g., GIF, BMP, PICT, WPG); the resolution is too low.
• Supply files that are too low in resolution.
• Submit graphics that are disproportionately large for the content.

Figures
Figures must be presented on separate sheets in consecutive order using Arabic numerals. Each figure should be provided with an instructive title and explanatory information. The legend should be typed separately from the figures. To ensure identification of the figures, indicate figure number and name of author using soft pencil. Submit original drawings in black ink on good quality white paper. High-contrast photographs are equally acceptable. One original set is required with the submission. Numbering and lettering of figures should be carefully accepted in order to ensure readability after

photographic reduction of the figure. Use only standard symbols to mark datapoints. Explanation of curves and symbols should be in the legend rather than part of the drawing, unless this is detrimental to clarity. Indicate SI units of measure in parentheses.

Colour illustrations should be submitted as original photographs, high-quality computer prints or transparancies, close to the size expected in publication or as 35 mm slides. Polaroid colour prints are *not* suitable. If, together with your accepted article, you submit usable colour figures then Elsevier will ensure , at no additional charge, that these figures will appear in colour on the web (e.g., ScienceDirect and other sites) regardless of whether or not these illustrations are reproduced in colour in the printed version. For colour reproduction in print, you will receive information regarding the total cost from Elsevier after receipt of your accepted article. For more detailed instructions please visit our artwork instruction pages at http://www.elsevier.com/artworkinstructions.

Please note: Because of technical complications which can arise by converting colour figures to 'grey scale' (for the printed version should you not opt for colour in print) please submit in addition usable black and white prints corresponding to all the colour illustrations.

A limited number of colour photographs are accepted free of charge with prior permission from the Editor-in-Chief. Colour photographs above this number will only be reproduced at the expense of the author(s). The 2006 price for colour figures is 285 Euro for the first page and 191 Euro for subsequent pages.

Figure captions
Ensure that each illustration has a caption. A caption should comprise a brief title (**not** on the figure itself) and a description of the illustration. Keep text in the illustrations themselves to a minimum but explain all symbols and abbreviations used.

Tables

Tables must be presented on separate sheets in consecutive order using Arabic numerals. The table headings must include a descriptive title and additional information to make the table self-explanatory. Some information may be given by using lower-case letter designations referring to footnotes at the bottom of the table. Indicate SI units of measure in parentheses.

References

References must be arranged as follows:

[1] A.– L. Cornaz, P. Buri, Nasal mucosa as an absorption barrier, Eur. J. Pharm. Biopharm. 40 (1994) 261– 270.

[5] C. Lanczos, Applied Analysis, Prentice-Hall, Englewood Cliffs, NJ, 1967, pp. 272– 280.

[10] D.M. Barends, Stability of active ingredients, in: H. Mü ller, W.H. Oeser (Eds.), Drug Master Files, Wissenschaftliche Verlagsgesellschaft mbH, Stuttgart, Germany, 1992, pp. 121– 128.

[14] E.A. Balazs, Ultrapure hyaluronic acid and the use thereof, U.S. Patent 4,141,973 (1979).

The system used by Chemical Abstracts (Chemical Abstracts Service Source Index) must be followed for the abbreviations of journals. Reference (4) is for patents, including the status, international country code, number of patent and year.
Articles in Special Issues: Please ensure that the words 'this issue' are added (in the list and text) to any references to other articles in this Special Issue.

Citation in text
Please ensure that every reference cited in the text is also present in the reference list (and vice versa). Any references cited in the abstract must be given in full. Unpublished results and personal communications are not recommended in the reference list, but may be mentioned in the text. If these references are included in the reference list they should follow the standard reference style of the journal and should include a substitution of the publication date with either 'Unpublished results' or 'Personal communication'. Citation of a reference as 'in press' implies that the item has been accepted for publication.

Web references
As a minimum, the full URL should be given and the date when the reference was last accessed. Any further information, if known (DOI, author names, dates, reference to a source publication, etc.), should also be given. Web references can be listed separately (e.g., after the reference list) under a different heading if desired, or can be included in the reference list.

References in a special issue
Please ensure that the words 'this issue' are added to any references in the list (and any citations in the text) to other articles in the same Special Issue.

Reference management software
This journal has standard templates available in key reference management packages EndNote (http://www.endnote.com/support/enstyles.asp) and Reference Manager (http://refman.com/support/rmstyles.asp). Using plug-ins to wordprocessing packages, authors only need to select the appropriate journal template when preparing their article and the list of references and citations to these will be formatted according to the journal style which is described below.

Reference formatting
There are no strict requirements on reference formatting at submission. References can be in any style or format as long as the style is consistent. Where applicable, author(s) name(s), journal title/book title, chapter title/article title, year of publication, volume number/book chapter and the pagination must be present. Use of DOI is highly encouraged. The reference style used by the journal will be applied to the accepted article by Elsevier at the proof stage. Note that missing data will be highlighted at proof stage for the author to correct. If you do wish to format the references yourself they should be arranged according to the following examples:

Reference style
Text: Indicate references by number(s) in square brackets in line with the text. The actual authors can be referred to, but the reference number(s) must always be given.
Example: '..... as demonstrated [3,6]. Barnaby and Jones [8] obtained a different result ....'
List: Number the references (numbers in square brackets) in the list in the order in which they appear in the text.
Examples:
Reference to a journal publication:
[1] J. van der Geer, J.A.J. Hanraads, R.A. Lupton, The art of writing a scientific article, J. Sci. Commun. 163 (2010) 51–59.
Reference to a book:
[2] W. Strunk Jr., E.B. White, The Elements of Style, fourth ed., Longman, New York, 2000.
Reference to a chapter in an edited book:
[3] G.R. Mettam, L.B. Adams, How to prepare an electronic version of your article, in: B.S. Jones, R.Z. Smith (Eds.), Introduction to the Electronic Age, E-Publishing Inc., New York, 2009, pp. 281–304.

Journal abbreviations source
Journal names should be abbreviated according to the List of Title Word Abbreviations: http://www.issn.org/services/online-services/access-to-the-ltwa/.

Video data

Elsevier accepts video material and animation sequences to support and enhance your scientific research. Authors who have video or animation files that they wish to submit with their article are strongly encouraged to include links to these within the body of the article. This can be done in the same way as a figure or table by referring to the video or animation content and noting in the body text where it should be placed. All submitted files should be properly labeled so that they directly relate to the video file's content. In order to ensure that your video or animation material is directly usable, please provide the files in one of our recommended file formats with a preferred maximum size of 50 MB. Video and animation files supplied will be published online in the electronic version of your article in Elsevier Web products, including ScienceDirect: http://www.sciencedirect.com. Please supply 'stills' with your files: you can choose any frame from the video or animation or make a separate image. These will be used instead of standard icons and will personalize the link to your video data. For more detailed instructions please visit our video instruction pages at http://www.elsevier.com/artworkinstructions. Note: since video and animation cannot be embedded in the print version of the journal, please provide text for both the electronic and the print version for the portions of the article that refer to this content.

AudioSlides

The journal encourages authors to create an AudioSlides presentation with their published article. AudioSlides are brief, webinar-style presentations that are shown next to the online article on ScienceDirect. This gives authors the opportunity to summarize their research in their own words and to help readers understand what the paper is about. More information and examples are available at http://www.elsevier.com/audioslides. Authors of this journal will automatically receive an invitation e-mail to create an AudioSlides presentation after acceptance of their paper.

Supplementary data

Elsevier accepts electronic supplementary material to support and enhance your scientific research. Supplementary files offer the author additional possibilities to publish supporting applications, high-resolution images, background datasets, sound clips and more. Supplementary files supplied will be published online alongside the electronic version of your article in Elsevier Web products, including ScienceDirect: http://www.sciencedirect.com. In order to ensure that your submitted material is directly usable, please provide the data in one of our recommended file formats. Authors should submit the material in electronic format together with the article and supply a concise and descriptive caption for each file. For more detailed instructions please visit our artwork instruction pages at http://www.elsevier.com/artworkinstructions.

Submission checklist

The following list will be useful during the final checking of an article prior to sending it to the journal for review. Please consult this Guide for Authors for further details of any item.

Ensure that the following items are present:

One author has been designated as the corresponding author with contact details:

- E-mail address
- Full postal address
- Telephone

All necessary files have been uploaded, and contain:

- Keywords
- All figure captions
- All tables (including title, description, footnotes)

Further considerations

- Manuscript has been 'spell-checked' and 'grammar-checked'
- All references mentioned in the Reference list are cited in the text, and vice versa
- Permission has been obtained for use of copyrighted material from other sources (including the Web)
- Color figures are clearly marked as being intended for color reproduction on the Web (free of charge) and in print, or to be reproduced in color on the Web (free of charge) and in black-and-white in print
- If only color on the Web is required, black-and-white versions of the figures are also supplied for printing purposes

For any further information please visit our customer support site at http://support.elsevier.com.

AFTER ACCEPTANCE

Use of the Digital Object Identifier

The Digital Object Identifier (DOI) may be used to cite and link to electronic documents. The DOI consists of a unique alpha-numeric character string which is assigned to a document by the publisher upon the initial electronic publication. The assigned DOI never changes. Therefore, it is an ideal medium for citing a document, particularly 'Articles in press' because they have not yet received their full bibliographic information. Example of a correctly given DOI (in URL format; here an article in the journal *Physics Letters B*):

http://dx.doi.org/10.1016/j.physletb.2010.09.059

When you use a DOI to create links to documents on the web, the DOIs are guaranteed never to change.

Online proof correction

Corresponding authors will receive an e-mail with a link to our online proofing system, allowing annotation and correction of proofs online. The environment is similar to MS Word: in addition to editing text, you can also comment on figures/tables and answer questions from the Copy Editor. Web-based proofing provides a faster and less error-prone process by allowing you to directly type your corrections, eliminating the potential introduction of errors.

If preferred, you can still choose to annotate and upload your edits on the PDF version. All instructions for proofing will be given in the e-mail we send to authors, including alternative methods to the online version and PDF.
We will do everything possible to get your article published quickly and accurately - please upload all of your corrections within 48 hours. It is important to ensure that all corrections are sent back to us in one communication. Please check carefully before replying, as inclusion of any subsequent corrections cannot be guaranteed. Proofreading is solely your responsibility. Note that Elsevier may proceed with the publication of your article if no response is received.

Offprints

The corresponding author, at no cost, will be provided with a PDF file of the article via e– mail. The PDF file is a watermarked version of the published article and includes a cover sheet with the journal cover image and a disclaimer outlining the terms and conditions of use.

Additional information

No responsibility is assumed by the Publisher for any injury and/or damage to persons or property as a matter of products liability, negligence or otherwise, or from any use or operation of any methods, products, instructions or ideas contained in the material herein. Because of the rapid advances made in the medical sciences, independent verification of diagnoses and drug dosages should be made.

Review of manuscripts

Upon receipt, a manuscript will be peer-reviewed. The reviewers' relevant comments and the editor's decision will be communicated to the authors.

TITLE

It should be carefully chosen to provide precise information about the contents and include important keywords. The title should be followed by the full name(s) of the author(s) and by his (her, their) affiliation(s). Different affiliations should be indicated by suitable superscripts.

To ensure identification of the corresponding author, please indicate full name, full postal address, e-mail address, phone and facsimile on the cover of the manuscript.

RESEARCH PAPERS

Should contain the following sections: Introduction, Theoretical Development (if applicable), Materials and Methods, Results, Discussion (or Results and Discussion) and References. For purely theoretical papers, appropriate sections may be selected.

USE OF DIGITAL OBJECT IDENTIFIER (DOI)

The digital object identifier (DOI) may be used to cite and link to electronic documents. The DOI consists of a unique alpha-numeric character string which is assigned to a document by the publisher upon the initial electronic publication. The assigned DOI never changes. Therefore, it is an ideal medium for citing a document particularly "Articles in press" because they have not yet received their full bibliographic information.

The correct format for citing DOI is shown as follows: doi:10.1016/j.ejpb.2004.10.006

Notes

The research and technical notes section of the journal (maximum 2500 words) is open to interesting results worthy of publication without requiring extensive introduction and discussion. This section should contain the following subheadings: Abstract, Introduction, Materials and Methods, Results and Discussion (combined). No more than 10 references should be used. Tables, figures and references are to be arranged according to research papers. Brevity of presentation is essential for this section. Five to 10 keywords should be provided.

Review articles

The organization and subdivision of review articles can be arranged at the author's discretion. Tables, figures and references are to be arranged according to research papers. An abstract, table of contents, and keywords are requested.

Correcting proofs and reprints

Elsevier will send PDF proofs to authors by e-mail for correction. If an author is unable to handle this process, regular print proofs will be sent. Elsevier will do everything possible to get the article corrected and published as quickly and accurately as possible. Therefore, it is important to ensure that all corrections are sent back in one communication. Subsequent corrections will not be possible. Only typesetting errors may be corrected; no changes in, or additions to, the accepted manuscript will be allowed. Proofs should be returned to Elsevier within 48 hours.

EJPB has no page charges. Fifty offprints of each paper will be supplied free of charge to the corresponding author. Additional offprints can be ordered at prices shown on the offprint order form that accompanies the copyright form.

AUTHOR INQUIRIES

For inquiries relating to the submission of articles (including electronic submission) please visit this journal's homepage. For detailed instructions on the preparation of electronic artwork, please visit http://www.elsevier.com/artworkinstructions. Contact details for questions arising after acceptance of an article, especially those relating to proofs, will be provided by the publisher. You can track accepted articles at http://www.elsevier.com/trackarticle. You can also check our Author FAQs at http://www.elsevier.com/authorFAQ and/or contact Customer Support via http://support.elsevier.com.

© Copyright 2014 Elsevier | http://www.elsevier.com